Evidence map›Paper›PMID 41676649›Full record

ArticlebioRxiv : the preprint server for biology2026

Regulation of virion production by the ORF8 signal peptide across SARS-CoV-2 variants.

Mir M Khalid, Irene P Chen, Frank S Soveg, Taha Y Taha, Takako Tabata, Rahul K Suryawanshi, Abdullah M Syed, Alison Ciling, Maria McCavitt-Malvido, Ursula Schulze-Gahmen and 11 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mir M KhalidGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Irene P ChenGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-5766-9253
Frank S SovegGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Taha Y TahaGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-7344-7490
Takako TabataGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Rahul K SuryawanshiGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Abdullah M SyedGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Alison CilingGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Maria McCavitt-MalvidoGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Ursula Schulze-GahmenGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Jennifer HayashiGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Ik-Jung KimBuck Institute for Research on Aging, Novato, CA, USA.
Siew Wai FongA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Jyoti BatraUniversity of California, San Francisco (UCSF), San Francisco, CA, USA.
G Renuka KumarGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Laurent ReniaA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Lisa Fp NgA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Nevan J KroganUniversity of California, San Francisco (UCSF), San Francisco, CA, USA.ORCID 0000-0003-4902-337X
Jennifer A DoudnaGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.
Eric VerdinBuck Institute for Research on Aging, Novato, CA, USA.
Melanie OttGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA, USA.

Funding

RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDREJ SALI · 2018 to 2026
$21.4M
Suppression of Host Antiviral Responses by a SARS-CoV-2 Histone MimeticF31AI164671 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, IRENE PO-RU · 2021 to 2022
$82k
NIAID NIH HHS F31 AI164671NIAID NIH HHS U19 AI135990
6 · The paper itself

Abstract

The open reading frame 8 (ORF8), an accessory protein of SARS-CoV-2, is prone to deletions and mutations across different viral variants, which was first described in several Singapore variants. The reason why viral evolution favors loss or inactivation of ORF8 is not fully understood, although the effects of ORF8 on inflammation, immune evasion, and disease severity have been described. Here we show -using clinical ORF8-deficient viral isolates, virus-like particles (VLPs) and viral replicons- that ORF8 expression dampens viral particle production. ORF8 physically interacts with the viral Spike protein and induces Golgi fragmentation, overall contributing to less virus particle production. Using systematic ORF8 deletions, we mapped the particle-reducing function to its N-terminal signal peptide. Interestingly, this part of ORF8 is severely truncated in the recent XBB.1.5 variant, and when restored, suppresses viral particle production in the context of the entire viral genome. Collectively, our data supports the model that evolutionary pressure exists to delete ORF8 sequence and expression across SARS-CoV-2 variants to fully enable viral particle production.

Indexed as

ORF8replicationSARS-CoV-2Signal peptideSpikeVLPXBB.1.5

Identifiers

PMID41676649
PMCPMC12889891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.